Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD

Experimental Neurology

Volumn 196, Issue 2, 2005, Pages 422-429

  Bibbiani, F ^a   Oh, J D ^b   Kielaite, A ^a   Collins, M A ^b   Smith, C ^a   Chase, T N ^a,c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CENTRAL MICHIGAN UNIVERSITY   (United States)

^c Hamilton Pharmaceuticals Inc   (United States)

Author keywords

AMPA; Dyskinesias; Levodopa; NMDA; Parkinson's

Indexed keywords

AMANTADINE; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; GYKI 47261; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SCORING SYSTEM;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZAZEPINES; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HAPLORHINI; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; ROTAROD PERFORMANCE TEST; TIME FACTORS;

EID: 27744571228     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.08.017     Document Type: Article

References (46)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 3 2001 448 458
2. D.W. Ali, and M.W. Salter NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity Curr. Opin. Neurobiol. 3 2001 336 342 (Crosswaite)
3. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 10 2001 1829 1834
4. F. Bibbiani, J.D. Oh, J.P. Petzer, N. Castagnoli, J.-F. Chen, M.A. Schwarzchild, and T.N. Chase A2A antagonist prevents dopamine agonist-induced motor complications in animal models of PD Exp. Neurol. 184 1 2003 285 294
5. P.J. Blanchet, S.M. Papa, L.V. Metman, M.M. Mouradian, and T.N. Chase Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease Neurosci. Biobehav. Rev. 21 1997 447 453
6. P.J. Blanchet, S. Konitsiotis, and T.N. Chase Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys Mov. Disord. 13 1998 798 802
7. P.J. Blanchet, J. Fang, M. Gillespie, L. Sabounjian, K.W. Locke, R. Gammans, M.M. Mouradian, and T.N. Chase Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease Clin. Neuropharmacol. 6 1998 339 343
8. C.A. Braz, V. Borges, and H.B. Ferraz Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study Clin. Neuropharmacol. 27 2004 25 29
9. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bédard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416
10. T.N. Chase Striatal plasticity and extrapyramidal motor dysfunction Parkinsonism Relat. Disord. 10 2004 305 313
11. T.N. Chase, and J.D. Oh Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann. Neurol. 47 4 Suppl. 1 2000 S122 S129
12. T.N. Chase, and J.D. Oh Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci. 10 2000 S86 S91 (Suppl.)
13. H.H. Cheung, and J.W. Gurd Tyrosine phosphorylation of the N-methyl-d-aspartate receptor by exogenous and postsynaptic density-associated Src-family kinases J. Neurochem. 3 2001 524 534
14. H.J. Chung, Y.H. Huang, L.F. Lau, and R.L. Huganir Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand J. Neurosci. 24 2004 10248 10259
15. A.J. Crossthwaite, H. Valli, and R.J. Williams Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones J. Neurochem. 88 2004 1127 1139
16. W. Danysz, C.G. Parsons, J. Kornhuber, W.J. Schmidt, and G. Quack Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-Preclinical studies Neurosci. Biobehav. Rev. 21 1997 455 468
17. M.A. Delfino, A.V. Stefano, J.E. Ferrario, I.R. Taravini, M.G. Murer, and O.S. Gershanik Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias Behav. Brain Res. 152 2 2004 297 306
18. R. Dingledine, K. Borges, D. Bowie, and S.F. Traynelis The glutamate receptor ion channels Pharmacol. Rev. 1 1999 7 61
19. A.W. Dunah, A.C. Sirianni, A.A. Fienberg, E. Bastia, M.A. Schwarzschild, and D.G. Standaert Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32 Mol. Pharmacol. 65 2004 121 129
20. T.M. Engber, S.M. Papa, R.C. Boldry, and T.N. Chase NMDA receptor blockade reverses motor response alterations induced by levodopa NeuroReport 5 1994 2586 2588
21. P.J. Hallett, and D.G. Standaert Rationale for and use of NMDA receptor antagonists in Parkinson's disease Pharmacol. Ther. 102 2004 155 174
22. T. Hayashi, and R.L. Huganir Tyrosine phosphorylation and regulation of the AMPA receptor by SRC family tyrosine kinases J. Neurosci. 24 2004 6152 6160
23. E. Hernández-Echeagaray, A.J. Starling, C. Cepeda, and M.S. Levine Modulation of AMPA currents by D2 dopamine receptors in striatal medium-sized spiny neurons: are dendrites necessary? Eur. J. Neurosci. 19 2004 2455 2463 (AMPA/D2)
24. A. Jimenez, M. Bonastre, M. Vila, Y. Agid, E.C. Hirsch, and E. Tolosa LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats Synapse 1 2001 40 47
25. Z. Juranyi, N. Sziray, B. Marko, G. Levay, and L.G. Harsing AMPA receptor blockade potentiates the stimulatory effect of l-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation Crit. Rev. Neurobiol. 16 2004 129 139
26. S. Konitsiotis, P.J. Blanchet, L. Verhagen, E. Lamers, and T.N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology 8 2000 1589 1595 (Juranyi Z)
27. S.A. Kotecha, and J.F. MacDonald Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission Int. Rev. Neurobiol. 54 2003 51 106
28. J.Y. Lin, R. Dubey, G.D. Funk, and J. Lipski Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons Brain Res. 2 2003 251 262
29. P.A. Loschmann, U. Wullner, M.T. Heneka, J.B. Schulz, M. Kunow, H. Wachtel, and T. Klockgether Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease Synapse 4 1997 381 391
30. E. Luginger, G.K. Wenning, S. Bosch, and W. Poewe Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease Mov. Disord. 5 2000 873 878
31. C. Marin, S.M. Papa, T.M. Engber, M. Bonastre, E. Tolosa, and T.N. Chase MK801 prevents levodopa-induced motor response alterations in parkinsonian rats Brain Res. 736 1996 202 205
32. C. Marin, A. Jimenez, M. Bonastre, T.N. Chase, and E. Tolosa Non-NMDA receptor mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats Synapse 36 2000 267 274
33. C. Marin, A. Jimenez, M. Bonastre, M. Vila, Y. Agid, E.C. Hirsch, and E. Tolosa LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats Synapse 1 2001 40 47
34. D. Merims, I. Ziv, R. Djaldetti, and E. Melamed Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease Lancet 353 1999 1764 1765
35. A. Nishi, J.A. Bibb, S. Matsuyama, M. Hamada, H. Higashi, A.C. Nairn, and P. Greengard Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A J. Neurochem. 4 2002 832 841
36. J.D. Oh, and T.N. Chase Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease Amino Acids 23 2002 133 139
37. J.D. Oh, C.L. Vaughan, and T.N. Chase Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits Brain Res. 2 1999 433 442
38. S.M. Papa, and T.N. Chase Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys Ann. Neurol. 5 1996 574 578
39. S.M. Papa, R.C. Boldry, T.M. Engber, A.M. Kask, and T.N. Chase Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade Brain Res. 701 1995 13 18
40. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2nd ed. 1986 Academic Press San Diego
41. N.P. Quinn Classification of fluctuations in patients with Parkinson's disease Neurology 51 1998 S25 S29
42. S.L. Swope, S.I. Moss, L.A. Raymond, and R.L. Huganir Regulation of ligand-gated ion channels by protein phosphorylation Adv. Second Messenger Phosphoprot. Res. 33 1999 49 78
43. A. Thomas, D. Iacono, A.L. Luciano, K. Armellino, A. Di Iorio, and M. Onofrj Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J. Neurol. Neurosurg. Psychiatry 75 2004 141 143
44. L. Verhagen Metman, P. Del Dotto, P. van den Munckhof, J. Fang, M.M. Mouradian, and T.N. Chase Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Neurology 50 1998 1323 1326
45. L. Verhagen Metman, P. Del Dotto, R. Natte, P. van den Munckhof, and T.N. Chase Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease Neurology 51 1998 203 206
46. R.H. Wessell, S.M. Ahmed, F.S. Menniti, G.L. Dunbar, T.N. Chase, and J.D. Oh NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemiparkinsonian rats Neuropharmacology 47 2004 184 194